Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options
During the last decade, we have seen tremendous progress in the therapy of lung cancer. Discovery of actionable mutations in <i>EGFR</i> and translocations in <i>ALK</i> and <i>ROS1</i> have identified subsets of patients with excellent tumor response to oral targ...
Main Authors: | Arpita Desai, Smitha P. Menon, Grace K. Dy |
---|---|
Format: | Article |
Language: | English |
Published: |
China Anti-Cancer Association
2016-03-01
|
Series: | Cancer Biology & Medicine |
Subjects: | |
Online Access: | http://www.cancerbiomed.org/index.php/cocr/article/view/910 |
Similar Items
-
ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells
by: Giulia Cesi, et al.
Published: (2017-06-01) -
The MEK/ERK Module Is Reprogrammed in Remodeling Adult Cardiomyocytes
by: Kubin Thomas, et al.
Published: (2020-09-01) -
Recombinant expression in E. coli of human FGFR2 with its transmembrane and extracellular domains
by: Adam Bajinting, et al.
Published: (2017-06-01) -
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
by: Jimin Yuan, et al.
Published: (2020-08-01) -
Global gene analysis identifying genes commonly regulated by the Ras/Raf/MEK and type I IFN pathways
by: Y. Komatsu, et al.
Published: (2015-06-01)